: FDA grants approval to Givlaari (givosiran) for the treatment of adult patients with acute hepatic porphyria, a genetic disorder resulting in the buildup of toxic porphyrin molecules which are formed during the production of heme (which helps bind oxygen in the blood)
from FDA Press Releases RSS Feed https://ift.tt/2OIaWBZ
via IFTTT
No comments:
Post a Comment